{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:52:20Z","timestamp":1778698340650,"version":"3.51.4"},"reference-count":54,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To provide an outline of the existing data on penile intraepithelial neoplasia (PeIN), as well as a narrative review on imiquimod (IQ; a toll\u2010like receptor 7 agonist) treatment and immune microenvironment markers that may predict response to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of the literature from 2000 to the present was conducted on PubMed, and we describe the most relevant data and cross references.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence of PeIN is increasing. Local therapy with IQ may offer an easy applicable treatment with complete response rates of up to 63% but can be associated with considerable side\u2010effects. There is no conclusive data on the optimal treatment schedule for PeIN, but evaluation of treatment results for other human papillomavirus\u2010related pre\u2010malignancies suggest three times a week for a duration up to 16\u2009weeks. There are no published studies concerning the PeIN immune microenvironment. However, findings from the few studies on penile cancer and pre\u2010cancerous vulvar and cervical lesions imply that specific immune cell subpopulations can serve as future predictors for successful immunomodulation treatments such as IQ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, limited data are available on IQ treatment for PeIN and no published data exists on the PeIN immune microenvironment. Further translational studies are warranted to gain more understanding on the pathophysiology of PeIN and potential predictors of progression and of response to topical treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16473","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T04:20:34Z","timestamp":1721362834000},"page":"881-889","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment"],"prefix":"10.1111","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-8935","authenticated-orcid":false,"given":"Ofir","family":"Avitan","sequence":"first","affiliation":[{"name":"Department of Urology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek Hospital  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tynisha","family":"Rafael","sequence":"additional","affiliation":[{"name":"Department of Urology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek Hospital  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4281-4814","authenticated-orcid":false,"given":"Manon","family":"Vreeburg","sequence":"additional","affiliation":[{"name":"Department of Urology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek Hospital  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7516-8762","authenticated-orcid":false,"given":"Laura","family":"Elst","sequence":"additional","affiliation":[{"name":"Department of Urology University Hospitals Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise M.","family":"Bekers","sequence":"additional","affiliation":[{"name":"Division of Pathology The Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-6586","authenticated-orcid":false,"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[{"name":"Department of Urology University Hospitals Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina S.","family":"Jordanova","sequence":"additional","affiliation":[{"name":"Department of Urology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek Hospital  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6244-0456","authenticated-orcid":false,"given":"Oscar","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Urology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek Hospital  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1800574"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3083"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(21)01050-2"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.083"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00246-5"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.36255\/exon-publications-urologic-cancers-epidemiology-penile-cancer"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2196\/34874"},{"key":"e_1_2_11_9_1","unstructured":"The Global Cancer Observatory (GCO) [Internet].https:\/\/gco.iarc.fr\/"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15688"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-021-01510-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30682-X"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.09.034"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13871"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.14824"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14488"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.07.025"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181cdad23"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181c76a49"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3203"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.75"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1825687"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2019.09.004"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402316"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.052"},{"key":"e_1_2_11_28_1","article-title":"Imiquimod for anogenital warts in non\u2010immunocompromised adults","volume":"2014","author":"Grillo\u2010Ardila CF","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.018"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12466"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-020-0327-4"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.02.027"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/095646240101200105"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70243-9"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.789"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100608"},{"key":"e_1_2_11_37_1","first-page":"3031","article-title":"Clinical and molecular responses in high\u2010grade intraepithelial neoplasia treated with topical imiquimod 5%","volume":"7","author":"Diaz\u2010Arrastia C","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2012.09.006"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31825bc6e8"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00469-X"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.06.003"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70456-5"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072685"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0560.2001.028003131.x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14996"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051432"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4760"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33168"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13709"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.01.009"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.09.021"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.07.018"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2009.009309"},{"key":"e_1_2_11_54_1","first-page":"642","article-title":"Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts","volume":"16","author":"Sch\u00f6fer H","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0327"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:42:46Z","timestamp":1761741766000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/bju.16473"],"URL":"https:\/\/doi.org\/10.1111\/bju.16473","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"2024-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}